非奈利酮在肾病合并2型糖尿病患者中的心血管事件
FIGARO-DKD为双盲随机对照试验,纳入7437例2型糖尿病合并CKD患者(尿白蛋白/肌酐比30–<300且eGFR 25–90 ml/min/1.73 m²,或尿白蛋白/肌酐比300–5000且eGFR≥60 ml/min/1.73 m²),随机接受非奈利酮或安慰剂,均在随机化前将RAS阻断剂调整至说明书最大耐受剂量。中位随访3.4年,主要复合终点(心血管死亡、非致死性心梗、非致死性卒中、心衰住院)非奈利酮组12.4% vs 安慰剂组14.2%(HR 0.87,95%CI 0.76–0.98,P=0.03),获益主要来自心衰住院减少(HR 0.71,95%CI 0.56–0.90)。肾脏复合终点HR 0.87(95%CI 0.76–1.01)。高钾血症相关停药非奈利酮组1.2% vs 安慰剂组0.4%。
要点
- 适用人群为2型糖尿病合并CKD:尿白蛋白/肌酐比30–<300且eGFR 25–90 ml/min/1.73 m²,或尿白蛋白/肌酐比300–5000且eGFR≥60 ml/min/1.73 m²。
- 主要心血管复合终点非奈利酮组12.4% vs 安慰剂组14.2%,HR 0.87(95%CI 0.76–0.98,P=0.03)。
- 获益主要来自心衰住院减少:HR 0.71(95%CI 0.56–0.90)。
- 肾脏复合终点(肾衰竭、eGFR持续下降≥40%、肾性死亡)非奈利酮组9.5% vs 安慰剂组10.8%,HR 0.87(95%CI 0.76–1.01)。
- 高钾血症相关停药非奈利酮组1.2% vs 安慰剂组0.4%,用药期间需关注血钾。
适用人群与场景
- 2型糖尿病合并CKD患者:尿白蛋白/肌酐比30–<300且eGFR 25–90 ml/min/1.73 m²(2–4期CKD),或尿白蛋白/肌酐比300–5000且eGFR≥60 ml/min/1.73 m²(1–2期CKD)。
- 随机化前RAS阻断剂已调整至说明书最大剂量且未出现不可接受副作用。
- 原文未提及急诊或ICU场景、排除人群的具体条目。
诊断标准与关键阈值
- CKD分期依据eGFR:eGFR 25–90 ml/min/1.73 m²对应2–4期CKD;eGFR≥60 ml/min/1.73 m²对应1–2期CKD。
- 白蛋白尿分层依据尿白蛋白/肌酐比(白蛋白以mg、肌酐以g计):30–<300为中度升高,300–5000为重度升高。
处置流程与药物剂量
- 第一步:确认2型糖尿病合并CKD且符合上述白蛋白尿与eGFR条件。
- 第二步:将RAS阻断剂调整至说明书最大剂量且不引起不可接受副作用后再随机化/启动非奈利酮(原文为随机化前调整)。
- 第三步:非奈利酮或安慰剂口服,具体剂量、频次原文未提及。
- 第四步:监测高钾血症,高钾血症相关停药非奈利酮组1.2%、安慰剂组0.4%。
红旗征与不能漏的情况
- 高钾血症导致停药:非奈利酮组1.2% vs 安慰剂组0.4%,需监测血钾。
- 原文未提及其他需立即处理或不能漏诊的情况。
研究设计与关键结果
- 研究类型:双盲随机对照试验(FIGARO-DKD,NCT02545049),由Bayer资助。
- 样本量与中心数:7437例患者接受随机化;中心数原文未提及。
- 人群:2型糖尿病合并CKD,符合上述白蛋白尿与eGFR条件,RAS阻断剂已调至最大耐受剂量。
- 干预与对照:非奈利酮 vs 安慰剂。
- 主要终点(心血管死亡、非致死性心梗、非致死性卒中、心衰住院复合):非奈利酮组458/3686(12.4%)vs 安慰剂组519/3666(14.2%),HR 0.87(95%CI 0.76–0.98,P=0.03)。
- 心衰住院:HR 0.71(95%CI 0.56–0.90)。
- 次要终点(肾衰竭、eGFR较基线持续下降≥40%、肾性死亡复合):非奈利酮组350例(9.5%)vs 安慰剂组395例(10.8%),HR 0.87(95%CI 0.76–1.01)。
- 安全性:总体不良事件频率两组无实质差异;高钾血症相关停药非奈利酮组1.2% vs 安慰剂组0.4%。
证据类型、等级与局限
- 证据类型:随机对照试验(双盲)。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未提及;设计上为药企资助试验。
对床旁实践的改变
- 对符合入组条件的2型糖尿病合并CKD患者,非奈利酮可改善心血管复合终点,主要减少心衰住院。
- 启动前需将RAS阻断剂调整至说明书最大耐受剂量(原文随机化前已调整)。
- 用药期间关注高钾血症,高钾血症相关停药率非奈利酮组1.2%高于安慰剂组0.4%。
- 不适用人群:原文未明确列出排除人群;不符合上述白蛋白尿与eGFR条件者不在本研究范围。
- 常见陷阱:原文未提及。
指南或共识出处
- 原文未提及指南或共识名称;研究为FIGARO-DKD(NCT02545049),发表于N Engl J Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear.
METHODS: In this double-blind trial, we randomly assigned patients with CKD and type 2 diabetes to receive finerenone or placebo. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300 and an estimated glomerular filtration rate (eGFR) of 25 to 90 ml per minute per 1.73 m2 of body-surface area (stage 2 to 4 CKD) or a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of at least 60 ml per minute per 1.73 m2 (stage 1 or 2 CKD). Patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary outcome, assessed in a time-to-event analysis, was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The first secondary outcome was a composite of kidney failure, a sustained decrease from baseline of at least 40% in the eGFR, or death from renal causes. Safety was assessed as investigator-reported adverse events.
RESULTS: A total of 7437 patients underwent randomization. Among the patients included in the analysis, during a median follow-up of 3.4 years, a primary outcome event occurred in 458 of 3686 patients (12.4%) in the finerenone group and in 519 of 3666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P = 0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90). The secondary composite outcome occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 1.01). The overall frequency of adverse events did not differ substantially between groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%).
CONCLUSIONS: Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).
参考来源
- Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021. PMID: 34449181. doi:10.1056/NEJMoa2110956
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。